The present invention relates to polypeptides binding Aggrecan as well asADAMTS5 and/or MMP13, more inparticular to polypeptides that comprise or essentially consist ofimmunoglobulins binding Aggrecan as well asimmunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (alsoreferred to herein as "polypeptides of the invention", and"immunoglobulin(s) of the invention", respectively). The invention alsorelates to constructs comprising such immunoglobulins, such asimmunoglobulin single variable domains (ISVDs) or polypeptides as well asnucleic acids encoding such immunoglobulins orpolypeptides (also referred to herein as "nucleic acid(s) of the invention"；to methods for preparing such immunoglobulins, polypeptides andconstructs； to host cells expressing or capable of expressing suchimmunoglobulins or polypeptides； to compositions, and in particularto pharmaceutical compositions, that comprise such immunoglobulins,polypeptides, constructs, nucleic acids and/or host cells； and touses of immunoglobulins, polypeptides, constructs, nucleic acids, host cellsand/or compositions, in particular for prophylactic and/ortherapeutic purposes, such as the prophylactic and/or therapeutic purposesmentioned herein. Other aspects, embodiments, advantages
